<div id="readability-page-1"><div><p>While there were no traditional IPOs this past week, three blank check companies priced, and several sizable deals joined the pipeline.</p><p>The week’s three blank check IPOs were led by <strong>Inflection Point Acquisition VI</strong> (IPFXU), which raised $220 million to target technology-enabled businesses.</p></div><p>Three SPACs also submitted initial filings. <strong>Collective Acquisition II</strong> (CAIIU) plans to raise $220 million, targeting finance, defense technology, and AI. <strong>Oceanhawk Acquisition</strong> (OHACU) plans to raise $200 million, backed by investment firm OceanHawk. <strong>Research Alliance III</strong> (RACC) plans to raise $50 million, formed by RA Capital.</p><div><table><thead><tr><th colspan="4">9 Filings During the Week of March 23rd, 2026</th></tr><tr><th>Issuer<br/><em>Business</em></th><th>Deal<br/>Size</th><th>Sector</th><th>Lead<br/>Underwriter</th></tr></thead><tbody><tr><td>Alamar Biosciences (ALMR)</td><td>$100M</td><td>Health Care</td><td>JP Morgan</td></tr><tr><td colspan="4"><em>Provides a protein biomarker detection platform for disease detection research.</em></td></tr><tr><td>Collective Acquisition II (CAIIU)</td><td>$220M</td><td>SPAC</td><td>Clear Street</td></tr><tr><td colspan="4"><em>Blank check company targeting finance, defense technology, and AI.</em></td></tr><tr><td>Kailera Therapeutics (KLRA)</td><td>$100M</td><td>Health Care</td><td>JP Morgan</td></tr><tr><td colspan="4"><em>Phase 3 biotech developing injectable and oral GLP-1s for obesity.</em></td></tr><tr><td>Yesway (YSWY)</td><td>$300M</td><td>Consumer Staples</td><td>Morgan Stanley</td></tr><tr><td colspan="4"><em>Convenience store chain with over 400 locations throughout seven states.</em></td></tr><tr><td>AsiaPac AdTechinno Group (APAT)</td><td>$25M</td><td>Technology</td><td>Maxim</td></tr><tr><td colspan="4"><em>Hong Kong-based adtech platform provider.</em></td></tr><tr><td>Arxis (ARXS)</td><td>$400M</td><td>Industrials</td><td>Goldman</td></tr><tr><td colspan="4"><em>Aerospace and defense electronics and components manufacturer.</em></td></tr><tr><td>Research Alliance III (RACC)</td><td>$50M</td><td>SPAC</td><td>Leerink Partners</td></tr><tr><td colspan="4"><em>Blank check company formed by RA Capital targeting drug development and healthtech.</em></td></tr><tr><td>Aevex (AVEX)</td><td>$200M</td><td>Industrials</td><td>Goldman</td></tr><tr><td colspan="4"><em>Provides military unmanned aircraft systems and services.</em></td></tr><tr><td>Oceanhawk Acquisition (OHACU)</td><td>$200M</td><td>SPAC</td><td>Benchmark</td></tr><tr><td colspan="4"><em>Blank check company backed by investment firm OceanHawk.</em></td></tr></tbody></table></div></div>

IPFXU

SBIO

CYTOF

<p>The week of March 23rd, 2026, saw significant filing activity in the aerospace and healthcare sectors, despite no traditional IPOs. Three blank check companies, including Inflection Point Acquisition VI, raised a total of $220 million targeting technology-enabled businesses. Other notable filings included Alamar Biosciences and Kailera Therapeutics, each raising $100 million in the healthcare sector. Additionally, several SPACs, such as Collective Acquisition II and Oceanhawk Acquisition, also entered the pipeline with substantial funding plans.</p>

RenaissanceCapital

Inflection Point Acquisition VI - Unit

ALPS Medical Breakthrough

ALTAMIRA THERAPEUTICS LTD

Aligos Therapeutics

Inflection Point  Acquisition

iShares US Pharma

Galera Therapeutics

Kalaris Therapeutics

Inflection Point Acquisition IV

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

VG Health

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Karyopharm Therap

Bleichroeder Acquisition I - Unit

Ark Genomic Revolution ETF

MBX Biosciences

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity